ATE535529T1 - Verfahren zur acylierung von maytansinol mit chiralen aminosäuren - Google Patents

Verfahren zur acylierung von maytansinol mit chiralen aminosäuren

Info

Publication number
ATE535529T1
ATE535529T1 AT06800952T AT06800952T ATE535529T1 AT E535529 T1 ATE535529 T1 AT E535529T1 AT 06800952 T AT06800952 T AT 06800952T AT 06800952 T AT06800952 T AT 06800952T AT E535529 T1 ATE535529 T1 AT E535529T1
Authority
AT
Austria
Prior art keywords
maytansinol
acylation
amino acids
chiral amino
chiral
Prior art date
Application number
AT06800952T
Other languages
English (en)
Inventor
Guojie Ho
Darren Carrozzella
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE535529T1 publication Critical patent/ATE535529T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06800952T 2005-08-09 2006-08-08 Verfahren zur acylierung von maytansinol mit chiralen aminosäuren ATE535529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70669405P 2005-08-09 2005-08-09
PCT/US2006/030857 WO2007021674A2 (en) 2005-08-09 2006-08-08 Method of acylating maytansinol with chiral amino acids

Publications (1)

Publication Number Publication Date
ATE535529T1 true ATE535529T1 (de) 2011-12-15

Family

ID=37758086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800952T ATE535529T1 (de) 2005-08-09 2006-08-08 Verfahren zur acylierung von maytansinol mit chiralen aminosäuren

Country Status (7)

Country Link
US (1) US7598375B2 (de)
EP (1) EP1913002B9 (de)
JP (1) JP5167130B2 (de)
AT (1) ATE535529T1 (de)
AU (1) AU2006280146B2 (de)
CA (1) CA2617953C (de)
WO (1) WO2007021674A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
EP2188311B1 (de) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon
WO2009099728A1 (en) 2008-01-31 2009-08-13 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
US20120121615A1 (en) * 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
EP3666289A1 (de) 2011-02-15 2020-06-17 ImmunoGen, Inc. Zytotoxische benzodiazepinderivate
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
ES2806146T3 (es) 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
EP3904358A1 (de) 2012-09-26 2021-11-03 ImmunoGen, Inc. Verbesserte verfahren zur acylierung von maytanisol
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN103254213B (zh) * 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
CN104530235A (zh) 2012-12-21 2015-04-22 百奥泰生物科技(广州)有限公司 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105188766B (zh) 2013-03-15 2019-07-12 瑞泽恩制药公司 生物活性分子、其偶联物及治疗用途
WO2014194274A2 (en) 2013-05-30 2014-12-04 Biogen Idec Ma Inc. Oncostatin m receptor antigen binding proteins
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
CN105585579A (zh) * 2014-10-24 2016-05-18 南京联宁生物制药有限公司 一种化合物及其制备方法以及美登素dm1的制备方法
CN104623687B (zh) * 2015-03-11 2017-09-05 中国科学院上海高等研究院 利用美登醇制备的抗体药物偶联物及其制备方法和应用
SG11201707585UA (en) 2015-03-17 2017-10-30 Regeneron Pharma Amino acid acylation reagents and methods of using the same
US20160375147A1 (en) 2015-03-27 2016-12-29 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
PT3956332T (pt) * 2019-04-18 2023-04-24 Indena Spa Processo diasterosselectivo para a preparação de ésteres de maitansinoides contendo tiol ou dissulfeto e seus intermediários
WO2024059267A1 (en) * 2022-09-16 2024-03-21 Immunogen, Inc. Improved methods for preparing n-methyl alanine esters of maytansinol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260609A (en) 1977-06-01 1981-04-07 Merck & Co., Inc. Di- and tri- substituted thiazoles
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7771727B2 (en) * 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7301019B2 (en) * 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters

Also Published As

Publication number Publication date
JP5167130B2 (ja) 2013-03-21
CA2617953A1 (en) 2007-02-22
AU2006280146A1 (en) 2007-02-22
US20070037972A1 (en) 2007-02-15
US7598375B2 (en) 2009-10-06
EP1913002A4 (de) 2010-10-27
EP1913002B1 (de) 2011-11-30
EP1913002B9 (de) 2012-04-25
EP1913002A2 (de) 2008-04-23
JP2009504655A (ja) 2009-02-05
AU2006280146B2 (en) 2012-06-28
WO2007021674A3 (en) 2007-07-26
CA2617953C (en) 2013-12-17
WO2007021674A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ATE535529T1 (de) Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
ATE475419T1 (de) Verfahren zur zubereitung von lansoprazol
DE602004032160D1 (de) Verfahren zur Zubereitung von Getränken
EP1912674B8 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
DE602005016292D1 (de) Verfahren zur herstellung von glatiramer
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
DE60321130D1 (de) Variation von parametern zur neurostimulation
DE602005019144D1 (de) Verfahren zur schmerzbehandlung in knochenkrebs du
WO2006102283A3 (en) Beta-lactamylalkanoic acids for treating premenstrual disorders
ATE515268T1 (de) Verwendung von op-1 zur behandlung von knorpeldefekten
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
DE60325381D1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
DE60333291D1 (de) Verfahren zur herstellung von flachglas
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
DE60331111D1 (de) Verfahren zur Herstellung von martensitaushärtendem Stahl
ATE440980T1 (de) Verfahren zur hydrolyse von polyphosphorsäure in geformten artikeln
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATA14432002A (de) Verbessertes verfahren zur singlet sauerstoff oxidation von organischen substraten